07/05/2022
•2024Viewpoint
Visby Connects with City and County Health Officials at NACCHO in Atlanta
Visby brings point-of-care PCR to the deep south with an appearance at NACCHO360.
Visby Joins the NACCHO360 Conference in Atlanta, GA
July 19-June 21, 2022
Hyatt Regency Atlanta
265 Peachtree St NE
Atlanta, GA 30303
Booth: 202
During the COVID-19 pandemic, sexually transmitted infection (STI) rates have risen to all time highs. Current STI testing takes too long and often leads to presumptive treatment, causing overuse of antibiotics or under-treatment of patients.
Learn more about the world’s first hand-held, point-of-care PCR testing device, created especially so clinicians can rapidly provide data-driven treatment and start to reverse the STI epidemic — stop by booth #202 at they Hyatt Regency in Atlanta, July 18-24.
Expected attendees: 1,300
Learn more about the Visby Medical Sexual Health Test
Read more articles & insights
CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test
The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today that it will award biotechnology company Visby Medical of San Jose, California, up to $1.8 million
Visby Medical™ Receives FDA Clearance and CLIA Waiver for second Generation Sexual Health Test for Women
Visby Medical™ announced today that it has received 510(k) clearance and was granted a CLIA waiver from the FDA for its 2nd generation point of
Visby Medical Receives FDA Emergency Use Authorization for Respiratory Health Test for Use in CLIA Waived Settings
Visby Medical announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for its Respiratory Health point of
Visby Medical Expands Series E Round to Over $135 Million
Visby Medical announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for its Respiratory Health point of
